Table 2.

PRCC for each model parameter at different combinations of treatment and vaccination coverages. Higher absolute values indicate that a parameter contributes a greater amount to the uncertainty in R_e.

			30% Vaccinated		35% Vaccinated		51% Vaccinated		60% Vaccinated
	Parameter		PRCC	p-Value	PRCC	p-Value	PRCC	p-Value	PRCC	p-Value
30% treated	Secondary attack rate	θ	0.996	<0.001	0.996	<0.001	0.996	<0.001	0.995	<0.001
	Antiviral treatment efficacy	εT	−0.862	<0.001	−0.860	<0.001	−0.845	<0.001	−0.826	<0.001
	Vaccine efficacy	εV	−0.353	<0.001	−0.422	<0.001	−0.623	<0.001	−0.727	<0.001
	Contact rate	c	0.354	<0.001	0.350	<0.001	0.328	<0.001	0.304	<0.001
	1/(Duration of infectious period)	δ	−0.098	<0.001	−0.097	<0.001	−0.091	<0.001	−0.085	<0.001
	Proportion of infected individuals hospitalized	pH	−0.029	0.003	−0.030	0.002	−0.033	0.001	−0.033	0.001
37% treated	Secondary attack rate	θ	0.994	<0.001	0.994	<0.001	0.994	<0.001	0.993	<0.001
	Antiviral treatment efficacy	εT	−0.871	<0.001	−0.870	<0.001	−0.861	<0.001	−0.849	<0.001
	Vaccine efficacy	εV	−0.286	<0.001	−0.346	<0.001	−0.551	<0.001	−0.661	<0.001
	Contact rate	c	0.284	<0.001	0.282	<0.001	0.268	<0.001	0.254	<0.001
	1/(Duration of infectious period)	δ	−0.079	<0.001	−0.078	<0.001	−0.075	<0.001	−0.072	<0.001
	Proportion of infected individuals hospitalized	pH	−0.024	<0.017	−0.025	0.013	−0.027	0.006	−0.029	<0.001
50% treated	Secondary attack rate	θ	0.988	<0.001	0.988	<0.001	0.987	<0.001	0.987	<0.001
	Antiviral treatment efficacy	εT	−0.887	<0.001	−0.886	<0.001	−0.883	<0.001	−0.878	<0.001
	Vaccine efficacy	εV	−0.204	<0.001	−0.250	<0.001	−0.425	<0.001	−0.540	<0.001
	Contact rate	c	0.199	<0.001	0.198	<0.001	0.192	<0.001	0.185	<0.001
	1/(Duration of infectious period)	δ	−0.057	<0.001	−0.060	<0.001	−0.055	<0.001	−0.054	<0.001
	Proportion of infected individuals hospitalized	pH	−0.018	0.072	−0.019	0.064	−0.021	0.037	−0.023	0.023